IL301596A - Pharmacy composition - Google Patents
Pharmacy compositionInfo
- Publication number
- IL301596A IL301596A IL301596A IL30159623A IL301596A IL 301596 A IL301596 A IL 301596A IL 301596 A IL301596 A IL 301596A IL 30159623 A IL30159623 A IL 30159623A IL 301596 A IL301596 A IL 301596A
- Authority
- IL
- Israel
- Prior art keywords
- mitapivat
- amount
- pediatric subject
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083834P | 2020-09-25 | 2020-09-25 | |
| US202063107196P | 2020-10-29 | 2020-10-29 | |
| US202163238483P | 2021-08-30 | 2021-08-30 | |
| PCT/US2021/051957 WO2022067039A1 (en) | 2020-09-25 | 2021-09-24 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301596A true IL301596A (en) | 2023-05-01 |
Family
ID=78179552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301596A IL301596A (en) | 2020-09-25 | 2021-09-24 | Pharmacy composition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230338283A1 (https=) |
| EP (1) | EP4216956A1 (https=) |
| JP (1) | JP2023542701A (https=) |
| KR (1) | KR20230074536A (https=) |
| AU (1) | AU2021347349A1 (https=) |
| CA (1) | CA3196829A1 (https=) |
| IL (1) | IL301596A (https=) |
| MX (1) | MX2023003431A (https=) |
| TW (1) | TW202228691A (https=) |
| WO (1) | WO2022067039A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CA2989111C (en) | 2015-06-11 | 2023-10-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| KR102777452B1 (ko) | 2017-11-22 | 2025-03-10 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 |
-
2021
- 2021-09-24 EP EP21791565.1A patent/EP4216956A1/en active Pending
- 2021-09-24 AU AU2021347349A patent/AU2021347349A1/en active Pending
- 2021-09-24 MX MX2023003431A patent/MX2023003431A/es unknown
- 2021-09-24 TW TW110135559A patent/TW202228691A/zh unknown
- 2021-09-24 JP JP2023519000A patent/JP2023542701A/ja active Pending
- 2021-09-24 WO PCT/US2021/051957 patent/WO2022067039A1/en not_active Ceased
- 2021-09-24 US US18/028,058 patent/US20230338283A1/en active Pending
- 2021-09-24 KR KR1020237013787A patent/KR20230074536A/ko active Pending
- 2021-09-24 IL IL301596A patent/IL301596A/en unknown
- 2021-09-24 CA CA3196829A patent/CA3196829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230338283A1 (en) | 2023-10-26 |
| TW202228691A (zh) | 2022-08-01 |
| KR20230074536A (ko) | 2023-05-30 |
| JP2023542701A (ja) | 2023-10-11 |
| EP4216956A1 (en) | 2023-08-02 |
| CA3196829A1 (en) | 2022-03-31 |
| WO2022067039A1 (en) | 2022-03-31 |
| AU2021347349A1 (en) | 2023-06-08 |
| MX2023003431A (es) | 2023-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295459A (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| IL257276A (en) | Methods for treating Knox-Gestaut syndrome using penforamine | |
| Sival et al. | Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial | |
| IL301910A (en) | Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults | |
| IL275115B2 (en) | Bis-choline tetrathiolmolybdate for the treatment of Wilson's disease | |
| CN111278440A (zh) | 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法 | |
| IL296865A (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL283069B1 (en) | Methods of administering corticosteroids | |
| US20200113883A1 (en) | Durable treatment with 4-aminopyridine in patients with demyelination | |
| IL297642A (en) | Methods for using t-type calcium channel modulators | |
| TW201729807A (zh) | 用於治療癲癇的方法 | |
| IL279220B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1s, 3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders | |
| IL316169A (en) | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease | |
| Fine | Age-related macular degeneration 1969–2004: a 35-year personal perspective | |
| IL301596A (en) | Pharmacy composition | |
| Nevmerzhitskaya et al. | Short-term safety and efficacy of Onasemnogene Abeparvovec in 10 patients with Spinal Muscular Atrophy: Cohort study | |
| IL302718A (en) | A tablet for use in the treatment of Huntington's disease and a method for its preparation | |
| IL301088A (en) | Ribitol treatment | |
| Byrne | Treatment of cognitive impairment in Alzheimer's disease | |
| IL292367A (en) | Methods for treating the symptoms of autism spectrum disorder | |
| CN116568281A (zh) | 药物制剂 | |
| Ross et al. | P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria | |
| IL303117A (en) | Preparations containing flumazenil and naltrexone and methods of using them | |
| IL297218A (en) | Pharmaceutical formulations | |
| IL292982A (en) | Methods of administering voxelotor |